Abstract
A series of novel C-aryl glucosides with substituents at the 3'-position or cyclization at 3', 4'-positions of the distal aryl ring were designed and synthesized, which might decrease the oxidative metabolism of dapagliflozin. Preliminary evaluation for hypoglycemic effect and the risk of hypoglycemia were carried out both in normal and in streptozotocin-induced diabetic mice. Among the synthesized compounds, compound 19a exerted potency-similarity with dapagliflozin and triggered the hypoglycemic effect in a dose-dependent manner. Besides, compound 19a, even at the high dose of 10 mg/kg, revealed a low risk of hypoglycemia. In further studies, 19a exhibited sustained antihyperglycemic effect without particular side-effects in 30-day chronic diabetic mice studies. Moreover, histological changes in the pancreas of diabetic mice indicated 19a might protect pancreatic β-cell from apoptosis by reducing the damage of glucotoxicity. All of these results demonstrated that compound 19a, with excellent in vivo pharmacological activity and safety profile, was considered to be a promising drug candidate for the treatment of diabetes mellitus.
References
Feb 1, 1996·Nature Genetics·M G MartínE M Wright
Jan 3, 2001·American Journal of Physiology. Renal Physiology·E M Wright
Jul 20, 2002·Bioorganic & Medicinal Chemistry Letters·Nathalie ChauretDeborah A Nicoll-Griffith
Apr 5, 2007·Current Medical Research and Opinion·Claresa Levetan
Feb 12, 2008·Journal of Medicinal Chemistry·Wei MengWilliam N Washburn
Sep 30, 2009·Journal of Medicinal Chemistry·Nicole C GoodwinDavid B Rawlins
Dec 10, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·M ObermeierW G Humphreys
Apr 15, 2010·JAMA : the Journal of the American Medical Association·Olivia J PhungCraig I Coleman
May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Aug 10, 2010·Journal of Medicinal Chemistry·Sumihiro NomuraMinoru Tsuda-Tsukimoto
Jan 11, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Wenbin ZhangYong-Xiang Wang
Mar 2, 2011·Diabetes·Michael J JurczakRichard G Kibbey
Mar 5, 2011·Kidney International. Supplement·James F List, Jean M Whaley
Mar 19, 2011·Journal of Medicinal Chemistry·Nicholas A Meanwell
Apr 1, 2011·Journal of Medicinal Chemistry·Vincent MascittiTong Zhu
Apr 30, 2011·Physiological Reviews·Ernest M WrightBruce A Hirayama
Nov 29, 2011·Journal of Molecular Modeling·Chunlei TangWenlong Huang
Dec 27, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Peter Mayer
Jan 17, 2012·Journal of Medicinal Chemistry·Nobuyuki NegoroYu Momose
Apr 12, 2012·Journal of Medicinal Chemistry·Nobuyuki NegoroYu Momose
Apr 18, 2012·Bioorganic & Medicinal Chemistry·Masakazu ImamuraMitsuaki Ohta
Jun 29, 2012·Clinical Pharmacology and Therapeutics·B ZambrowiczD R Powell
Oct 10, 2013·Integrative Biology : Quantitative Biosciences From Nano to Macro·Edina C Wang, Andrew Z Wang
Oct 10, 2013·Clinical Pharmacokinetics·Sreeneeranj KasichayanulaDavid W Boulton
Jan 25, 2014·Journal of Medicinal Chemistry·Ge XuXun Sun
Sep 9, 2010·ACS Medicinal Chemistry Letters·Nobuyuki NegoroYu Momose
Dec 3, 2014·Chemical Biology & Drug Design·Xuekun WangHai Qian